Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Interest & Investment Income (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Interest & Investment Income data on record, last reported at $3.4 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 6.74% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $12.7 million, down 7.72%, while the annual FY2025 figure was $12.7 million, 7.72% down from the prior year.
  • Interest & Investment Income reached $3.4 million in Q4 2025 per MIRM's latest filing, up from $3.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.1 million in Q3 2023 and bottomed at $65000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $2.2 million, with a median of $3.0 million recorded in 2025.
  • Peak YoY movement for Interest & Investment Income: plummeted 80.25% in 2021, then skyrocketed 3196.92% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $65000.0 in 2021, then surged by 3196.92% to $2.1 million in 2022, then soared by 76.15% to $3.8 million in 2023, then fell by 15.13% to $3.2 million in 2024, then grew by 6.74% to $3.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $3.4 million in Q4 2025, $3.3 million in Q3 2025, and $3.0 million in Q2 2025.